EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Treatment Discontinuation After Achieving MRD Negativity in Multiple Myeloma in the Pre‐BCMA Era: A Prospective, Single‐Centre Study

Kota Sato iD, Kenshi Suzuki, Shotaro Sugita, Ukyo Kondo, Miyu Watanabe, Moe Yogo, Tomomi Takei, Mizuki Ogura, Yu Abe, Taku Kikuchi, Nobuhiro Tsukada, Tadao Ishida

eJHaem · 2026-04 · 7 (2)

DOI: 10.1002/jha2.70281 ↗

Kurz gefasst

Fachartikel in der Zeitschrift eJHaem, online erschienen am 06.04.2026. Verfasst von Kota Sato und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology Japanese Red Cross Medical Center Shibuya-ku Tokyo Japan. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Minimal/measurable residual disease (MRD) negativity in multiple myeloma (MM) is associated with favourable outcomes; nonetheless, evidence supporting treatment discontinuation remains limited. We evaluated the feasibility of discontinuing antimyeloma therapy in patients with MRD negativity.

Methods

We analysed 41 patients who discontinued therapy after achieving MRD negativity at the 10 −5 level in the bone marrow (BM) and on imaging studies. Treatment regimens and lines of therapy were not prespecified. After discontinuation, patients were monitored with periodic MRD assessments. Salvage therapy was initiated at disease progression. For isolated BM‐MRD conversion, treatment decisions were made jointly by the investigator and the patient.

Results

The 2‐ and 3‐year treatment‐free survival (TFS) rates were 71.2% (95% CI, 54.0–83.0) and 67.9% (95% CI, 50.1–80.4), respectively, with the median not reached. Among the 34 patients with > 2 years of follow‐up, 19 (55.9%) maintained MRD negativity at 2 years. High‐risk cytogenetic abnormalities were associated with shorter TFS, whereas a BM normal plasma cell proportion ≥ 0.003% at discontinuation was associated with prolonged TFS.

Conclusions

Treatment discontinuation may be feasible in selected patients with MM who achieve and sustain MRD negativity, particularly in those without high‐risk cytogenetics or with normal plasma cell recovery in the BM. Trial Registration : The authors have confirmed clinical trial registration is not needed for this submission.

Schlagwörter

Stichwörter der Autor:innen

autologous stem cell transplantationhigh‐risk cytogenetic abnormalitiesminimal/measurable residual diseasemultiple myelomatreatment‐free survival

Autor:innen und Institutionen

  • Department of Hematology Japanese Red Cross Medical Center Shibuya-ku Tokyo Japan.

ORCID-Profile: Kota Sato

Zitieren

APA

Sato, K., Suzuki, K., Sugita, S., Kondo, U., Watanabe, M., Yogo, M., Takei, T., Ogura, M., Abe, Y., Kikuchi, T., Tsukada, N., & Ishida, T. (2026). Treatment Discontinuation After Achieving MRD Negativity in Multiple Myeloma in the Pre‐BCMA Era: A Prospective, Single‐Centre Study. eJHaem, 7(2). https://doi.org/10.1002/jha2.70281

Vancouver

Sato K, Suzuki K, Sugita S, Kondo U, Watanabe M, Yogo M, et al. Treatment Discontinuation After Achieving MRD Negativity in Multiple Myeloma in the Pre‐BCMA Era: A Prospective, Single‐Centre Study. eJHaem. 2026;7(2). doi:10.1002/jha2.70281

BibTeX
@article{Sato2026,
  author = {Sato, Kota and Suzuki, Kenshi and Sugita, Shotaro and Kondo, Ukyo and Watanabe, Miyu and Yogo, Moe and Takei, Tomomi and Ogura, Mizuki and Abe, Yu and Kikuchi, Taku and Tsukada, Nobuhiro and Ishida, Tadao},
  title = {Treatment Discontinuation After Achieving MRD Negativity in Multiple Myeloma in the Pre‐BCMA Era: A Prospective, Single‐Centre Study},
  journal = {eJHaem},
  year = {2026},
  volume = {7},
  number = {2},
  doi = {10.1002/jha2.70281}
}
Kostenlos starten →